Companies › BlueRock Therapeutics
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Ophthalmology, Neurology; next expected readout Oct 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| bemdaneprocel Midbrain dopaminergic neuron progenitors derived from human embryonic stem cells | TH | Phase 3 | Parkinsons Disease (PD) | Oct 2028 |
| OpCT-001 Photoreceptor precursor cells derived from human induced pluripotent stem cells (iPSCs) | – | Phase 1 | Primary Photoreceptor Disease | Oct 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06944522 | bemdaneprocel | Phase 3 | Parkinsons Disease (PD) | Neurology | Oct 2028 |
| NCT06789445 | OpCT-001 | Phase 1 | Primary Photoreceptor Disease | Ophthalmology | Oct 2029 |
–
AO GENERIUM Elpida Therapeutics SPC Beacon Therapeutics GenSight Biologics Ace Cells Lab
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.